不同剂量吸入噬菌体疗法对小鼠铜绿假单胞菌肺部感染的影响
在中性粒细胞减少BALB/c小鼠铜绿假单胞菌肺部感染模型中,感染后2小时经气道给予靶向铜绿假单胞菌的噬菌体PEV31三个剂量或磷酸缓冲盐溶液。感染后24小时,各噬菌体治疗组肺部细菌载量均显著下降1.3-1.9 log10,与给药剂量无关;噬菌体复制程度与剂量负相关,噬菌体耐药亚群随剂量增加而增多。
要点
- 感染后24小时,三个噬菌体治疗组肺部细菌载量均下降1.3-1.9 log10,与剂量无关。
- 噬菌体复制程度与给药剂量负相关,A、B、C组滴度分别增加6.2、2.7、9 log10。
- 肺部匀浆中噬菌体耐药亚群随剂量增加:A组30%、B组74%、C组91%。
核心结论
- 本研究提供了吸入噬菌体疗法的剂量-反应效应,可能为人类铜绿假单胞菌呼吸道感染的剂量选择提供指导。
研究设计与样本
- 中性粒细胞减少BALB/c小鼠经气管接种多重耐药铜绿假单胞菌2×10^4菌落形成单位,感染后2小时分别给予PEV31三个剂量或磷酸缓冲盐溶液。
- PEV31剂量为7.5×10^4(A组)、5×10^6(B组)、5×10^8(C组)空斑形成单位。
- 感染后2小时和24小时处死小鼠(n=5-7),收集肺、肾、脾、肝、支气管肺泡灌洗液和血液进行细菌和噬菌体计数。
主要发现
- 感染后24小时,所有噬菌体治疗组肺部细菌载量均显著下降1.3-1.9 log10,与给药剂量无关。
- 噬菌体复制程度与给药剂量负相关,A、B、C组滴度分别增加6.2、2.7、9 log10。
- 感染后24小时肺匀浆中噬菌体耐药细菌亚群随治疗剂量增加,A、B、C组分别为30%、74%、91%。
- 耐药突变体对环丙沙星敏感性增加、蹭行运动受损、蓝绿色色素产生减少。
- 随着PEV31治疗剂量增加,炎症细胞因子(IL-1β、IL-6和TNF-α)表达受到抑制。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Inhaled phage therapy has been revisited as a potential treatment option for respiratory infections caused by multidrug-resistant Pseudomonas aeruginosa; however, there is a distinct gap in understanding the dose-response effect. The aim of this study was to investigate the dose-response effect of Pseudomonas-targeting phage PEV31 delivered by the pulmonary route in a mouse lung infection model. METHODS: Neutropenic BALB/c mice were infected with multidrug-resistant P. aeruginosa (2 × 104 colony-forming units) through the intratracheal route and then treated with PEV31 at three different doses of 7.5 × 104 (Group A), 5 × 106 (Group B), and 5 × 108 (Group C) plaque-forming units, or phosphate-buffered saline at 2 hours postinoculation. Mice (n = 5-7) were euthanized at 2 hours and 24 hours postinfection, and lungs, kidneys, spleen, liver, bronchoalveolar lavage fluid, and blood were collected for bacteria and phage enumeration. RESULTS: At 24 hours postinfection, all phage-treated groups exhibited a significant reduction in pulmonary bacterial load by 1.3-1.9 log10, independent of the delivered phage dose. The extent of phage replication was negatively correlated with the dose administered, with log10 titre increases of 6.2, 2.7, and 9 for Groups A, B, and C, respectively. Phage-resistant bacterial subpopulations in the lung homogenate samples harvested at 24 hours postinfection increased with the treatment dose (i.e. 30%, 74%, and 91% in respective Groups A-C). However, the mutants showed increased susceptibility to ciprofloxacin, impaired twitching motility, and reduced blue-green pigment production. The expression of the inflammatory cytokines (IL-1ß and IL-6, and TNF-α) was suppressed with increasing PEV31 treatment dose. DISCUSSION: This study provides the dose-response effect of inhaled phage therapy that may guide dose selection for treating P. aeruginosa respiratory infections in humans.
引用
- Chang RYK, Chow MYT, Wang Y, et al. The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clin Microbiol Infect. 2022. PMID: 35123053. doi:10.1016/j.cmi.2022.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。